HOCPF:OTC-HOYA Corporation (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 115.14

Change

-4.86 (-4.05)%

Market Cap

USD 40.85B

Volume

200.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOF EssilorLuxottica Société ano..

N/A

USD 108.14B
ESLOY Essilor International SA

N/A

USD 106.30B
HOCPY Hoya Corp

N/A

USD 49.96B
CLPBY Coloplast A

-0.16 (-1.23%)

USD 29.67B
CLPBF Coloplast A/S

N/A

USD 29.67B
TRUMF Terumo Corporation

-1.19 (-6.15%)

USD 29.21B
SAUHF Straumann Holding AG

N/A

USD 26.17B
OCPNF Olympus Corporation

N/A

USD 22.43B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 20.85B
SDMHF Sartorius Stedim Biotech S.A

-17.55 (-8.24%)

USD 20.72B

ETFs Containing HOCPF

DBJP Xtrackers MSCI Japan Hedg.. 0.00 % 0.47 %

+1.88 (+0.95%)

USD 0.44B
DXJH 0.00 % 0.48 %

N/A

N/A
EWJ iShares MSCI Japan ETF 0.00 % 0.47 %

+0.93 (+0.95%)

N/A
FLJH Franklin FTSE Japan Hedge.. 0.00 % 0.09 %

+0.84 (+0.95%)

USD 0.08B
FLJP Franklin FTSE Japan ETF 0.00 % 0.09 %

+0.31 (+0.95%)

USD 2.18B
CSJP:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

+189.50 (+0.95%)

USD 0.72B
HMJD:LSE HSBC ETFs Public Limited .. 0.00 % 0.00 %

+0.45 (+0.95%)

N/A
HMJP:LSE HSBC MSCI JAPAN UCITS ETF 0.00 % 0.00 %

+37.00 (+0.95%)

N/A
IJPA:LSE iShares Core MSCI Japan I.. 0.00 % 0.00 %

+0.52 (+0.95%)

N/A
IJPD:LSE iShares Public Limited Co.. 0.00 % 0.00 %

+1.66 (+0.95%)

N/A
IJPE:LSE iShares MSCI Japan EUR He.. 0.00 % 0.00 %

+2.02 (+0.95%)

N/A
IJPN:LSE iShares MSCI Japan UCITS .. 0.00 % 0.00 %

+15.50 (+0.95%)

N/A
IJPU:LSE iShares MSCI Japan UCITS .. 0.00 % 0.00 %

+0.19 (+0.95%)

N/A
JPEH:LSE SPDR® MSCI Japan EUR Hdg.. 0.00 % 0.00 %

+1.48 (+0.95%)

USD 0.03B
JPJP:LSE SPDR® MSCI Japan UCITS E.. 0.00 % 0.00 %

+0.54 (+0.95%)

USD 91.59B
JPXG:LSE 0.00 % 0.00 %

N/A

N/A
JPXU:LSE Lyxor UCITS JPX-Nikkei 40.. 0.00 % 0.00 %

+4.35 (+0.95%)

USD 0.01B
JPXX:LSE Lyxor UCITS JPX-Nikkei 40.. 0.00 % 0.00 %

+409.00 (+0.95%)

USD 9.86M
LCJD:LSE Amundi MSCI Japan (DR) UC.. 0.00 % 0.00 %

+0.20 (+0.95%)

USD 572.76B
LCJG:LSE Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

+0.44 (+0.95%)

USD 9.93M
LCJP:LSE Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

+0.17 (+0.95%)

USD 572.76B
SJPA:LSE iShares Core MSCI Japan I.. 0.00 % 0.00 %

+47.50 (+0.95%)

N/A
IJPH:LSE iShares MSCI Japan GBP He.. 0.00 % 0.00 %

+2.59 (+0.95%)

N/A
UB02:LSE UBS MSCI Japan UCITS JPY .. 0.00 % 0.00 %

+50.50 (+0.95%)

N/A
UB0D:LSE UBS(Lux)Fund Solutions .. 0.00 % 0.00 %

+48.75 (+0.95%)

N/A
UC65:LSE UBS (Lux) Fund Solutions .. 0.00 % 0.00 %

+0.60 (+0.95%)

USD 115.53B
XDNG:LSE db x-trackers JPX-Nikkei .. 0.00 % 0.00 %

+58.00 (+0.95%)

N/A
XDNS:LSE Xtrackers MSCI Japan ESG .. 0.00 % 0.00 %

+14.00 (+0.95%)

N/A
XDNU:LSE db x-trackers JPX-Nikkei .. 0.00 % 0.00 %

+0.74 (+0.95%)

N/A
XDNY:LSE Xtrackers MSCI Japan ESG .. 0.00 % 0.00 %

+0.17 (+0.95%)

N/A
XMJD:LSE Xtrackers - MSCI Japan UC.. 0.00 % 0.00 %

+1.04 (+0.95%)

N/A
XMJG:LSE 0.00 % 0.00 %

N/A

N/A
XMJP:LSE Xtrackers MSCI Japan UCIT.. 0.00 % 0.00 %

+74.00 (+0.95%)

N/A
XMUJ:LSE Xtrackers - MSCI Japan UC.. 0.00 % 0.00 %

+0.91 (+0.95%)

N/A
UB0C:LSE 0.00 % 0.00 %

N/A

N/A
CJPU:LSE iShares VII PLC - iShares.. 0.00 % 0.00 %

+2.28 (+0.95%)

USD 0.77B
SAJP:LSE iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

+0.06 (+0.95%)

USD 1.43B
SDJP:LSE iShares MSCI Japan ESG Sc.. 0.00 % 0.00 %

+0.06 (+0.95%)

USD 0.43B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.35% 65% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.35% 63% D 54% F
Trailing 12 Months  
Capital Gain -7.38% 61% D- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.38% 59% D- 50% F
Trailing 5 Years  
Capital Gain 50.22% 77% C+ 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.22% 75% C 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 10.41% 57% F 56% F
Dividend Return 10.41% 52% F 52% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.00% 81% B- 76% C+
Risk Adjusted Return 38.57% 81% B- 75% C
Market Capitalization 40.85B 97% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector